Pilot Study of a Suprachoroidal Retinal Prosthesis

Overview

This study will be an initial proof of concept study, to evaluate safety and efficacy of a prototype suprachoroidal retinal implant

Full Title of Study: “Safety and Feasibility Study of a Prototype Suprachoroidal Retinal Prosthesis for Vision Restoration”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2014

Interventions

  • Device: Prototype wide view suprachoroidal retinal prosthesis
    • Manufacturer = Bionics Institute, Australia

Arms, Groups and Cohorts

  • Experimental: Suprachoroidal retinal prosthesis

Clinical Trial Outcome Measures

Primary Measures

  • Safety
    • Time Frame: 18 months
    • Number of device-related serious adverse events

Secondary Measures

  • Ability to perceive visual percepts during device stimulation
    • Time Frame: 18 months
    • Number of participants able to perceive phosphenes when the device is stimulated

Participating in This Clinical Trial

Inclusion Criteria

  • Aged 18 years or older – Either gender – A confirmed history of outer retinal degenerative disease such as retinitis pigmentosa or choroideremia – Remaining visual acuity of bare light perception or less in both eyes – Functional inner retina (ganglion cells and optic nerve), as shown by the ability to perceive light and/or a measurable corneal electrically evoked visual response – A history of at least 10 years of useful form vision in the worse seeing eye – Must be willing and able to comply with the testing and follow-up protocol demands (preferably residing within 1.5 hours of the investigational site) Exclusion Criteria:

  • Optic nerve disease (history of glaucoma of more than 1 month, or history of any other optic neuropathy) – Diseases of the inner retina including, but not limited to, central retinal artery or vein occlusion (CRAO, CRVO), end stage diabetic retinopathy, retinal detachment, traumatic retinal damage, infectious retinal disease, inflammatory retinal disease. – Inability to visualise the retina due to corneal or other ocular media opacities (corneal degenerations, dense cataracts, trauma, lid malpositions) – Any ocular condition that predisposes the subject to rubbing their eyes – Cognitive deficiencies, including dementia or progressive neurological disease – Psychiatric disorders, including depression, as diagnosed by a qualified psychologist – Deafness or significant hearing loss – Inability to speak or understand English – Pregnancy – Presence of a cochlear implant – Subject enrolled in another investigational drug or device trial for the treatment of their ocular condition – Poor general health, which would exclude them from obtaining a general anaesthetic – Unrealistic expectations of the bionic eye device

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Center for Eye Research Australia
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Anthony Burkitt, PhD, Study Director, Bionic Vision Australia
    • Robyn Guymer, MBBS, PhD, Principal Investigator, Centre for Eye Research Australia

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.